10 Feb 06
Prescribing indications based on successful clinical trials in sepsis
By J Carlet
Critical Care Medicine 34(2): 525-529
This is a point of view article commenting on the indications given several years ago to drotrecogin alpha (activated) for severe sepsis. This appears necessary following the recent publication of studies looking at subgroups within the initial PROWESS study, of the phase IV ENHANCE study, and of the results of two recent randomized clinical trials looking at the efficacy of this compound: the ADDRESS trial (with an editorial) and a pediatric study (not yet published), both recently stopped for futility.